re: Will you get the corona virus vaccine when it's available

quote:

---

Word is the problem with this man made disease is it never goes away since it has hiv like properties in that if you get it you get it forever. Supposedly the disease loves antibodies, which could explain why people get it a second time and often results are far worse the second time. With all the true and fake info out there it is hard to say what is actually real. But supposing those statements are true a vaccine will not help.

---

quote:

---

I was vaccinated in the Army for pretty much everything so I'm good.

---

Were you vaccinated for the coronavirus while you were in the Army?

quote:

---

Will you get the corona virus vaccine when it's available
The scare may be over by the time vaccine hits the market.

---

i love how alcohol consumption is linked to killing the virus.

in other words, drink a corona to avoid the coronavirus.

There is unlikely to be a vaccine. Efforts to create a vaccine for SARS (2003) and MERS (2012) all failed. The current one is SARS2 which causes COVID-19. To date there has never been a vaccine for a corona virus. They mutate too fast.

quote:

---

Not even New Orleans is considered that densely populated compared to other cities. It's only around 2,000 people per square mile.

---

Agreed, but NOLA is coming out of Mardi Gras, tons of people from all over coming in to celebrate it and LA families going all over the globe for the off week. Hopefully it was too early in it spreading.

quote:

---

I’ll just keep washing my hands.

---

This. Went to a buffet today and carried in a travel bottle of Purell. I used it after touching the handles for the food before actually starting to eat. Got a couple of weird looks but idkaf if it keeps me from getting sick. Let their nasty asses get it.

the scare will be over by June

Maybe sooner:
From Time Magazine (for those who still think it ain't a checkout line rag)

Moderna Therapeutics, a biotech company based in Cambridge, Mass., has shipped the first batches of its COVID-19 vaccine. The vaccine was created just 42 days after the genetic sequence of the COVID_19 virus, called SARS-CoV-2, was released by Chinese researchers in mid-January. The first vials were sent to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in Bethesda, MD, which will ready the vaccine for human testing as early as April.

NIH scientists also began testing an antiviral drug called remdesivir that had been developed for Ebola, on a patient infected with SARS-CoV-2. The trial is the first to test a drug for treating COVID-19, and will be led by a team at the University of Nebraska Medical Center. The first patient to volunteer for the ground-breaking study is a passenger who was brought back to the US after testing positive for the disease aboard the Diamond Princess. Others diagnosed with COVID-19 who have been hospitalized will also be part of the study.

Remdesivir showed encouraging results among animals infected with two related coronaviruses, one responsible for severe acute respiratory syndrome (SARS) and another for causing Middle East respiratory syndrome (MERS). Volunteers will be randomly assigned to receive either the drug or a placebo intravenously for 10 days, and they will have blood tests and nose and throat swabs taken every two days to track the amount of virus in their bodies. Even if the drug shows some efficacy in keeping blood levels of SARS-CoV-2 from growing, it could help to contain spread of the infection.

Moderna’s vaccine against COVID-19 was developed in record time because it’s based on a relatively new genetic method that does not require growing huge amounts of virus. Instead, the vaccine is packed with mRNA, the genetic material that comes from DNA and makes proteins. Moderna loads its vaccine with mRNA that codes for the right coronavirus proteins which then get injected into the body. Immune cells in the lymph nodes can process that mRNA and start making the protein in just the right way for other immune cells to recognize and mark them for destruction.

As Dr. Stephen Hoge, president of Moderna, told TIME earlier this month, “mRNA is really like a software molecule in biology. So our vaccine is like the software program to the body, which then goes and makes the [viral] proteins that can generate an immune response.” That means that this vaccine method can be scaled up quickly, saving critical time when a new disease like COVID-19 emerges and starts infecting tens of thousands of people.